Clinical Trials Browser

Lymphoma, Non-Hodgkin × tocilizumab × 30 days × Clear all

Lymphoma, Non-Hodgkin

NCT04077723 2026-05-29

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

498 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT03434730 2026-05-26

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Phase 2 Completed

46 enrolled 8 charts

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT05169515 2026-05-18

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

121 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

Clinical Trials

MorningSun

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma